Free Trial

Tempest Therapeutics (TPST) Competitors

Tempest Therapeutics logo
$10.27 -0.51 (-4.73%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$10.01 -0.26 (-2.58%)
As of 10/10/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TPST vs. CRBP, MCRB, MIST, AVTX, SAVA, ELDN, PEPG, GNLX, IXHL, and ACTU

Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Corbus Pharmaceuticals (CRBP), Seres Therapeutics (MCRB), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Cassava Sciences (SAVA), Eledon Pharmaceuticals (ELDN), PepGen (PEPG), Genelux (GNLX), Incannex Healthcare (IXHL), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

Tempest Therapeutics vs. Its Competitors

Corbus Pharmaceuticals (NASDAQ:CRBP) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-3.26
Tempest TherapeuticsN/AN/A-$41.84M-$14.59-0.70

In the previous week, Tempest Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Tempest Therapeutics and 4 mentions for Corbus Pharmaceuticals. Tempest Therapeutics' average media sentiment score of 0.63 beat Corbus Pharmaceuticals' score of 0.62 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corbus Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tempest Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 3.6% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Corbus Pharmaceuticals' return on equity of -43.65% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus PharmaceuticalsN/A -43.65% -39.62%
Tempest Therapeutics N/A -334.76%-130.63%

Corbus Pharmaceuticals presently has a consensus target price of $45.43, indicating a potential upside of 192.33%. Tempest Therapeutics has a consensus target price of $30.00, indicating a potential upside of 192.11%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than Tempest Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
Tempest Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Corbus Pharmaceuticals has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.08, indicating that its share price is 308% less volatile than the S&P 500.

Summary

Corbus Pharmaceuticals beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TPST vs. The Competition

MetricTempest TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$47.87M$2.65B$6.10B$10.63B
Dividend YieldN/A56.72%5.67%4.71%
P/E Ratio-0.7022.9185.2726.57
Price / SalesN/A745.20612.78132.59
Price / CashN/A179.8938.5062.09
Price / Book1.815.3712.726.53
Net Income-$41.84M$32.78M$3.30B$275.96M
7 Day Performance-1.25%2.02%0.89%-0.77%
1 Month Performance-4.11%7.68%6.29%3.67%
1 Year Performance-22.93%-1.76%80.41%37.30%

Tempest Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TPST
Tempest Therapeutics
2.0992 of 5 stars
$10.27
-4.7%
$30.00
+192.1%
-28.2%$47.87MN/A-0.7020News Coverage
Analyst Forecast
CRBP
Corbus Pharmaceuticals
3.9247 of 5 stars
$14.52
-2.1%
$45.43
+212.9%
-15.2%$181.74MN/A-3.0540Analyst Forecast
MCRB
Seres Therapeutics
2.1409 of 5 stars
$21.00
+2.0%
$14.33
-31.7%
+24.2%$180.26M$126.32M-4.57330Analyst Forecast
MIST
Milestone Pharmaceuticals
2.2171 of 5 stars
$2.12
+0.5%
$4.50
+112.3%
+35.4%$179.34M$1M-2.5230News Coverage
Analyst Forecast
AVTX
Avalo Therapeutics
3.2151 of 5 stars
$14.00
+4.5%
$31.67
+126.2%
+37.7%$176.24M$440K0.0040Positive News
SAVA
Cassava Sciences
2.495 of 5 stars
$3.57
-1.7%
$2.00
-44.0%
-85.0%$175.36MN/A-1.4030Analyst Forecast
ELDN
Eledon Pharmaceuticals
2.1291 of 5 stars
$2.86
+0.7%
$10.00
+249.7%
+1.9%$170.06MN/A-2.4410News Coverage
Positive News
Analyst Forecast
PEPG
PepGen
3.4227 of 5 stars
$4.96
-3.3%
$8.40
+69.4%
-45.6%$168.26MN/A-1.6830Analyst Forecast
Gap Down
GNLX
Genelux
1.2588 of 5 stars
$4.54
+2.0%
$20.33
+347.9%
+93.5%$168.09M$10K-5.2810News Coverage
Positive News
Analyst Forecast
IXHL
Incannex Healthcare
0.7202 of 5 stars
$0.44
-7.7%
N/A-75.4%$167.52M$90K-0.373News Coverage
Analyst Forecast
Gap Up
ACTU
Actuate Therapeutics
1.8791 of 5 stars
$7.02
+0.6%
$20.33
+189.6%
+8.8%$162.24MN/A0.0010Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TPST) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners